Anzeige
Mehr »
Login
Donnerstag, 19.09.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Gold erreicht in diesem Jahr 33 Mal ein neues Rekordhoch, aber diese Minenaktie ist die eigentliche Geschichte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
1.289 Leser
Artikel bewerten:
(2)

Ocutrx Technologies, Inc: Ocutrx Acquires 25 Year FDA & Hi-Reliability Manufacturing Company to Advance Capabilities for Medical Devices

Ocutrx purchased Spectrum AMT, Inc. for vertical integration

IRVINE, Calif. and COLORADO SPRINGS, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Ocutrx Technologies, a global technology company developing revolutionary medical devices with augmented reality (AR), extended reality (XR) and artificial intelligence (AI), announces today its strategic acquisition of Spectrum Advanced Manufacturing Technologies, Inc., a Colorado-based electronics manufacturing and assembly company. With this acquisition, the consolidated Oxutrx_Spectrum company now has seven (7) process lines, including ISO Optics Lab capabilities, serving medical, commercial and government entities. Spectrum is known for providing Hi-Rel hardware and New Product Introduction (NPI) support to its diverse customer base along the Colorado Front Range with a premier quality legacy of over 25 years for many defense, NASA and commercial space flight programs. Spectrum also provides microelectronics, wiring and harnessing, and assembly for many Fortune 500 DOD and aerospace contractors.

The mid-cap acquisition will fuel Ocutrx's efforts to repatriate its supply chain and leverage Spectrum's infrastructure to produce innovative devices, like the OcuLenzTM AR/XR medical headsets, in compliance with FDA standards on U.S. soil. Ocutrx will also work with Spectrum's Fortune 500 clients like Lockheed-Martin, Raytheon, Honeywell, Northrop Grumman, Honeybee Robotics, Barber-Nichols, and NASA, enabling growth opportunities in new non-medical verticals including the aerospace, robotics, 5G, 5G-MEC, automotive, gaming and AR/XR defense markets.

Ocutrx, a Tier One customer with Qualcomm®, is leveraging the latest in AR, virtual reality, and AI headset technologies with the Qualcomm XR-2 Chipsets, to build its breakthrough AR devices for Healthcare and other verticals. Among its products is the OcuLenz AR headset which improves the experience of those suffering from Age-Related Macular Degeneration and its OR- Bot Surgical Visualization Theatre® with the ORLenz® AR/XR Surgery headsets which improve ergonomics and visualization for surgeons of all disciplines. With the Spectrum acquisition, Ocutrx intends to expand its products' applications within and beyond the medical field furthering AR integrations globally. Ocutrx is introducing its OR-Bot 4900D Surgery Visualization Theatre at the Frankfurt Retina Meeting 2023in Frankfurt, Germany on April 14-17.

"The acquisition of a revenue positive, EBITDA positive company which can build our OR-Bot 3D Surgery Visualization Theatres and AR headsets in compliance with FDA, CE and MDR standards is a huge milestone for us in controlling our growth and in healthcare generally. It is also a quantum leap to bring new 3D visualization and AI tools for surgeons in the operating room." Ocutrx CEO Michael A. H. Freeman said, "And, the fact that the DOD and Fortune 500 companies are looking more and more for AR/XR and AI solutions creates a unique opportunity out of this business combination integration."

The global augmented reality marketsize is anticipated to reach USD 597.54 billion by 2030, expanding at a CAGR of 40.9% from 2022 to 2030, according to the latest report by Grand View Research, Inc. The growth of the market can be attributed to the growing adoption of augmented reality (AR) technology in various end-use industries and industry verticals, including automotive, healthcare, and education, among others.

"Spectrum's deep relationships with industry leaders will give Ocutrx access to programs and business metrics inside and outside the Medical Device field allowing Ocutrx to broaden its product applications and further integrate AR into global industries," said Jim Gatzimas who serves the role of Chief Business Development Officer for the consolidated companies and manages the East Coast (Boston) Company Offices, "while also positioning Spectrum to meet market demands and drive technology development ensuring long-term success."

The founder and current Spectrum CEO, Jeff Riggs is staying on as a minority partner with Ocutrx and will remain CEO of Spectrum for several years to permit Ocutrx and Spectrum to fully integrate, "The complementary talents of Ocutrx and Spectrum AMT will allow for a streamlined and integrated new product development cycle for Ocutrx to get quality products to market faster and more efficiently," Mr. Riggs said, "Spectrum AMT leadership and employees remain committed to our core competency of providing agile manufacturing support to our valued customers."

Sage Consulting and Wealth Preservation, Inc. serves in the capacity as Administrative Agent for the loan facility funded by the individual and family officer lenders who provided transaction financing.

A team from Howard & Howard Attorneys PLLCserved as Acquisition Counsel for Ocutrx. The Team consisted of: Author O. Rogers, Christopher Warburton, Bryan Clark, and Gary Peters. Seaton Curran, served as IP and Patent Counsel. Howard & Howard was founded over 153 years ago and is a full-service business law firm with both a national and international practice. It provides legal services to businesses and business owners.

Withers Bergman LLPacted as counsel to the Administrative Agent in connection with the financing transaction.

About Ocutrx:

With corporate headquarters in the OC at Irvine, California, a research and R&D lab in Oklahoma, and a manufacturing facility in Colorado Springs Ocutrx is a new breed of medical manufacturing company focusing on 3D visualization innovations, including Augmented Reality/Extended Reality.

About Spectrum AMT:

Founded in 1997 to manufacture medical devices in compliance with FDA regulations and provide quick-turn product development and manufacturing services to commercial and government entities, Spectrum Advanced Manufacturing Technologies, Inc. is a multi-process line circuit card manufacturing and assembly facility based in Colorado Springs, Colorado. Spectrum serves a robust client base in Hi-Rel industries such as medical devices, industrial controls, defense and space flight hardware. For more information please visit https://spectrumamt.com/.

michelle@kafkamediagroup.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6400745-cdec-4895-92af-d5942fb65234


© 2023 GlobeNewswire (Europe)
Besser als NVIDIA! 3 KI- Favoriten mit riesigem Potenzial

Erleben Sie die KI-Revolution und sichern Sie sich gigantische Gewinne!

Nutzen Sie die einmalige Gelegenheit, die Ihnen die Künstliche Intelligenz bietet! Unser exklusiver Aktienreport enthüllt drei unglaublich aussichtsreiche KI-Aktien, die von der bahnbrechenden Entwicklung in diesem Sektor massiv profitieren können.

Warum sollten Sie dabei sein?

Weil eine Investition in KI-Unternehmen nicht nur Stabilität bringt, sondern auch das Potenzial hat, Ihr Depot explosionsartig wachsen zu lassen. Die letzten Jahre haben bewiesen: Wer auf KI setzt, kann außergewöhnliche Gewinne einfahren. Jetzt, nach einer kurzen Konsolidierungsphase, öffnen sich wieder sensationelle Einstiegsmöglichkeiten.

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche KI-Aktien das größte Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen die besten Investments im KI-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.